APGE — Apogee Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Apogee Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -39.8 | -84 | -182 | -256 |
| Depreciation | ||||
| Non-Cash Items | 13.5 | 3.12 | 12.8 | 42.5 |
| Other Non-Cash Items | ||||
| Changes in Working Capital | 9.81 | 6.11 | -2 | -15.5 |
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Cash from Operating Activities | -16.4 | -74.8 | -171 | -227 |
| Capital Expenditures | — | -0.167 | -1.15 | -5.15 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | — | -274 | -299 | -174 |
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Cash from Investing Activities | — | -274 | -300 | -180 |
| Net Issuance / Retirement of Stock | ||||
| Cash from Financing Activities | 168 | 315 | 495 | 396 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 152 | -33.3 | 23.5 | -10.5 |